Scarica l'app Stockscreener
15.92
0.38%
-0.06
Dopo l'orario di chiusura:
15.85
-0.07
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$15.98
Aprire:
$15.95
Volume 24 ore:
9.37M
Relative Volume:
1.08
Capitalizzazione di mercato:
$18.34B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-5.0221
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
+0.95%
1M Prestazione:
+25.75%
6M Prestazione:
+49.48%
1 anno Prestazione:
+43.94%
Intervallo 1D:
$15.77
$16.00
Intervallo di 1 settimana:
$15.59
$16.07
Portata 52W:
$6.85
$16.30
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
15.92 | 18.41B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.66 | 58.95B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.78 | 53.73B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.27 | 49.47B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.22 | 39.98B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.42 | 20.69B | 3.13B | 1.27B | 1.12B | 26.39 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - MSN
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation - Seeking Alpha
Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Bef - GuruFocus
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline - Finviz
Where is Viatris Inc. (VTRS) headed according to the Street? - MSN
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
(VTRS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Viatris Inc (VTRS) May Struggle to Outperform: A Look at Fut - GuruFocus
How Do Investors Really Feel About Viatris Inc? - Sahm
Can Viatris Inc. sustain its profitabilityJuly 2025 Levels & Daily Chart Pattern Signals - mfd.ru
Is Viatris Inc. impacted by rising ratesWeekly Trend Summary & Technical Confirmation Alerts - mfd.ru
Is Viatris (VTRS) Quietly Repositioning Its Deal-Making Strategy With a New Chief Legal Officer? - simplywall.st
Viatris (VTRS) Shares Cross 3% Yield Mark - Nasdaq
Viatris Continues Support of SBP, Celebrates Restoration of 250th Home Damaged by Hurricane Maria - CSRwire
Viatris Inc. stock rises Monday, outperforms market - MSN
JPMorgan Adjusts Price Target on Viatris to $16 From $14, Maintains Neutral Rating - marketscreener.com
Viatris stock hits 52-week high at $15.61 By Investing.com - Investing.com Australia
Chris Davis's Strategic Acquisition of Viatris Inc. Shares - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse - FinancialContent
Viatris stock hits 52-week high at $15.61 - Investing.com
Indiana wins $6.25 million in settlement with pharmaceutical companies - starcitytv.com
Where is Viatris Inc. (VTRS) Headed According to the Street? - Finviz
Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS) - The Globe and Mail
Viatris 2022 Sustainability Report: Building Foundations To Advance Diversity, Equity and Inclusion - CSRwire
Why Viatris (VTRS) Stock Is Up Today - The Globe and Mail
Viatris Stock Hits 52-Week High After UBS Buy Rating & $18 Price Target | Market Update 2026News and Statistics - IndexBox
Why Viatris (VTRS) Shares Are Rising Today - Bitget
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Indiana reaches $6.25M settlement with pharmaceutical companies over EpiPen prices - Indianapolis Business Journal
Viatris gains as UBS upgrades to Buy (VTRS:NASDAQ) - Seeking Alpha
US drugmaker Viatris appoints in-house pharma veteran as next CLO - The Global Legal Post
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Viatris to Buy From Neutral, Adjusts Price Target to $18 From $11 - marketscreener.com
A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment - Yahoo Finance
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)? - simplywall.st
Responsive Playbooks and the VTRS Inflection - Stock Traders Daily
Inflation Data: Is Viatris Inc impacted by rising ratesMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
What are Wall Street analysts' target price for Viatris stock? - MSN
Viatris Announces Chief Legal Officer Transition and Successor - The Globe and Mail
Viatris Inc (VTRS) Stock Price Up 5.3% on Feb 4 - GuruFocus
Viatris Appoints Matthew J. Maletta as Chief Legal Officer - The Malaysian Reserve
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 - Sahm
Viatris to Report Fourth Quarter and Full Year 2025 Financial Re - GuruFocus
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viatris Inc Azioni (VTRS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Le Goff Corinne | Chief Commercial Officer |
Sep 11 '25 |
Sale |
10.25 |
7,032 |
72,045 |
35,299 |
1.48%
0.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):